Ocugen (OCGN) Short-term Investments (2017 - 2023)

Ocugen's (OCGN) quarterly Short-term Investments came in at $8.5 million in Q1 2023, down 36.71% on a QoQ basis from $13.4 million in Q4 2022.

Ocugen (OCGN) Short-term Investments (2017 - 2023) Analysis & Trends

Ocugen (OCGN) has 4 years of Short-term Investments data on file, last reported at $8.5 million in Q1 2023.

Quarterly Short-term Investments changed N/A year-over-year to $8.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $8.5 million (changed N/A YoY) and the FY2022 annual result came in at $13.4 million, changed N/A from the prior year.
Short-term Investments retreated to $8.5 million in Q1 2023, from $13.4 million in the prior quarter.
In the past five years, Short-term Investments ranged from a high of $13.4 million in Q4 2022 to a low of $5.0 million in Q1 2021.
A 3-year average of $7.4 million and a median of $5.0 million in 2021 frame the typical range for Short-term Investments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Ocugen	457.71 Mn	357.61 Mn	-

Download Data